HOME | 中文 | ENGLISH
Home
About Us
Wuxi Beita
Changsha Beita
Cooperation Units
Intellectual Property
Academic Publications
Qualification
Products
Radioisotope Labeled Products
Stable Isotope Labeled Products
Services
Technology Advantages
Labeling Service
Detection and Analysis Services
Customers
News
Beita News
Industry News
Media Coverage
Contact Us
Feedback
Information List
Japan's Shimadzu to buy clinical isotope labeling company AlsaChim
2017-06-22
Instrument Information Network 2017/06/22 [Introduction] In the face of the global wave of clinical mass spectrometry, even Shimadzu, which rarely participates in capital operation, has recently revealed acquisition news: Shimadzu announced that it has wholly acquired AlsaChim, an independent contract research and development institution in France, through Shimadzu Europe. The global scientific instrument industry is changing, and the merger and acquisition integration between enterprises is continuous. However, compared with the "frequent moves" of European and American companies such as Syme Fly and Danaher, the mergers and acquisitions of Japanese companies appear to be "implicit" a lot. Nevertheless, in the face of global clinical mass spectrometry waves.
China's Food and Drug Administration Becomes a Full Member of the International Technical Coordination Committee for Registration of Medicines for Human Use (ICH)
2017-06-19
On June 19, 2017, the State Food and Drug Administration announced that it has become a full member of the International Technical Coordination for Registration of Medicines for Human Use (ICH). It means that China's drug regulatory authorities, pharmaceutical industry and R & D institutions will gradually transform and implement the highest international technical standards and guidelines, and actively participate in the formulation of rules, which will promote innovative drugs to meet the clinical drug needs of patients at home and abroad as soon as possible, and enhance the innovation ability and international competitiveness of the domestic pharmaceutical industry. ICH was established in 1990 by the United States, the European Community and Japan tripartite drug regulatory authorities and industry associations, and in.
Wuxi Beta establishes partnership with Swiss RC TRITECH
2017-05-15
On May 15, 2017, Wuxi Beta Pharmaceutical Technology Co., Ltd. established a cooperation with Swiss RCTRITECH Company to provide technical services for tritium labeling for new drug development in China. In our country, the tritium label of drugs has not been provided by professional companies. This cooperation will provide great convenience for our customers who need tritium label and open up a shortcut for the development of tritium label technology in our country.
Wuxi Beta Obtain C- 14 and H-3 Radiation Safety License
On May 15, 2017, Wuxi Beta Pharmaceutical Technology Co., Ltd. completed the construction of a non-sealed radioactive material workplace and obtained a C- 14 and H-3 radiation safety license. Wuxi Beta has been engaged in the simulation research and development of C14 labeled precursor compounds since 2009 and the cooperative research and development of C14 source materials since 2010. By October 2016, these tasks have been basically completed and a solid foundation for development has been established. At this time, the acquisition of radiation safety license marks the formal opening of China's professional C14 marking service.
Ministry of Agriculture "Guidelines for Metabolic Testing of Pesticides in Plants" (draft for comments)
2017-05-07
Excerpt: Issued by: Ministry of Agriculture of China Issued on May 7, 2017. Isotope labeling synthesis of 3.2 pesticides The process of isotope labeling synthesis of pesticide molecules (stable skeletons) using radioactive and (or) stable isotopes to obtain 13C, 14C, 15N and 35S labeled pesticide compounds. In general, 14C is preferred, and when the molecule contains no carbon atoms or only unstable carbon-containing side chains, 35S or other radioactive isotopes are contemplated. Stable isotopes (such as 13C and 15N) are used together with radioactive isotopes to help metabolism
Technical Summary Exchange Meeting of China Nuclear Power Research and Design Institute Held in Chengdu
2016-10-29
On October 29, 2016, China Nuclear Power Research and Design Institute held a technical summary exchange meeting in Chengdu, announcing the success of the localization of C14 source materials. In September 2010, under the coordination and guidance of Academician Zhou Yongmao and Academician Sun Yufa, Wuxi Beta Pharmaceutical Technology Co., Ltd. established a cooperative relationship with China Nuclear Power Research and Design Institute. After 6 years of unremitting efforts, it finally overcame the difficulties. The localization of C14 source materials was realized, and a solution was established for the international shortage of C14.
Jiangyin High-tech Zone Established Fourth Nobel Prize Winner Research Institute
2016-07-11
Reprint: Binhai High-tech Network News Binhai High-tech Network News Recently, Wuxi Beta Pharmaceutical Technology Co., Ltd. joined hands with Nobel Prize winner Professor Robert Grubb to set up the Grubb Isotope Labeling China (Jiangyin) Research Institute in Jiangyin High-tech Zone, and the "Academician Zhou Yongmao Workstation" of the Chinese Academy of Engineering was also set up at the same time. So far, Jiangyin has introduced five Nobel laureates and established four Nobel laureates. In recent years, Jiangyin City has attached great importance to the work of scientific and technological talents, and has fully implemented the "High-level Talent Gathering Plan" including the "Nobel Prize Winners Gathering Plan", "Academician Gathering Plan", and "Overseas Engineer Gathering Plan". This time with the grid
Wuxi Beta and Shanghai Medissi Biotechnology Co., Ltd. to establish a cooperative relationship
2016-06-24
On June 24, 2016, Wuxi Beta Pharmaceutical Technology Co., Ltd. and Shanghai Medisi Biotechnology Co., Ltd. signed a framework agreement to complement each other's advantages and do their best to cooperate in the development of C14 labeling of Chinese medicine and animal drug generation research. Actively promote the development of my country's new drug development industry.
Technical guidelines for non-clinical pharmacokinetic studies of drugs
2014-05-13
Excerpt: Release Unit: china food and drug administration Release Date: May 13, 2014 2. Selection of Radioisotope Labeling Methods Low-energy radioisotopes commonly used in ADME research of small molecule chemical drugs are carbon -14(14C) and tritium (3H). 14C labeling is the most commonly used, its biological background is low, biology almost no isotope effect and affect metabolism, rarely occur isotope exchange, sensitivity is higher than 3H and easy to quantify. Metabolically stable sites should be selected when labeling carbon -14 compounds. In vivo testing unless 14C labeling is very difficult or
● Beita News
● Industry News
● Media Coverage